Pharma major Sun Pharmaceutical Industries and Israel-based Moebius Medical signed an exclusive global licensing deal to develop liposomal non-opioid pain product for osteoarthritis.
About the Deal:
Moebius Medical will conduct requisite pre-clinical studies, and will assume responsibility for product development and manufacturing through the end of Phase-II studies.
Sun Pharma will assume responsibility for further clinical studies, regulatory submissions and product commercialisation. Moebius Medical will receive an upfront payment, development-based and sales-based milestone payments, and tiered royalties on sales from Sun Pharma
According to the pact, Sun Pharma will fund further development of Moebius Medical’s product, MM-II, and undertake its global commercialisation.
Present Stage of Development:
Till now, Moebius Medical has completed a first-in-man clinical study at Hadassah Medical Center, demonstrating the product’s fast onset of action and its potentially better efficacy and comparable safety for alleviating osteoarthritis pain as compared to Hyaluronic Acid injection, said the release.